Short-term effect of atorvastatin on endothelial function in healthy offspring of parents with type 2 diabetes mellitus

Cardiovascular Therapeutics

Volumn 26, Issue 4, 2008, Pages 253-261

  Amudha, Kadirvelu ^a,b   Choy, Anna Maria ^b,c   Mustafa, Mohamed R ^b   Lang, Chim C ^b,c  

^a MONASH UNIVERSITY MALAYSIA   (Malaysia)

^b UNIVERSITY OF MALAYA   (Malaysia)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Diabetes mellitus; Endothelial function; Statins

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; CELL ADHESION MOLECULE; INTERLEUKIN 6; LIPID;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MARKER; DOUBLE BLIND PROCEDURE; ENDOTHELIAL DYSFUNCTION; FEMALE; FLOW MEDIATED DILATION; HOMEOSTASIS MODEL OF INSULIN RESISTANCE; HUMAN; HUMAN EXPERIMENT; INFLAMMATION; INSULIN RESISTANCE INDEX; LIPID BLOOD LEVEL; MALE; MEASUREMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; NORMAL HUMAN; PARENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELATIVE; VASCULAR ENDOTHELIUM; VASODILATATION;

ADOLESCENT; ADULT; BLOOD FLOW VELOCITY; BLOOD GLUCOSE; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INSULIN; MALE; PYRROLES; VASODILATION; YOUNG ADULT;

EID: 55849146705     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2008.00064.x     Document Type: Article

References (32)

1. Beck Nielsen H, Groop LC. Metabolic and genetic characterization of pre-diabetic states: sequence of events leading to non-insulin dependent diabetes mellitus. J Clin Invest 1994 94 : 1714 1721.
2. Ryder E, Gomez ME, Fernandez V, Campos G, Morales LM, Valbuena H, Raleigh X. Presence of impaired insulin secretion and insulin resistance in normoglycemic male subjects with family history of type 2 diabetes. Diab Res Clin Pract 2003 60 : 95 103.
3. Krolewski AS, Czyzyka A, Kopczynski J, Rywik S. Prevalence of diabetes mellitus, coronary artery disease and hypertension in the families of insulin dependent and insulin-independent diabetics. Diabetologia 1981 21 : 520 524.
4. Hsueh WA, Lyon CJ, Quinones MJ. Insulin resistance and endothelium. Am J Med 2004 117 : 109 117.
5. Goldfine AB, Beckman JA, Betensky RA, Devlin H, Hurley S, Varo N, Schonbeck U, Klizabeth M, Creager M. Family history of diabetes is a major determinant of endothelial function. J Am Coll Cardiol 2006 47 : 2456 2461.
6. Caballero AE, Arora S, Saouaf R, Lim SC, Smakowski P, Park JY, King GL, Logerfo FW, Horton ES, Veves A. Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes 1999 48 : 1856 1862.
7. Balletshofer BM, Rittig K, Enderle MD, Volk A, Maerker E, Jacob S, Matthaei S, Rett K, Haring HU. Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance. Circulation 2000 101 : 1780 1784.
8. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction and adverse long-term outcome of coronary heart disease. Circulation 2000 101 : 1899 1906.
9. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001 104 : 2673 2678.
10. Widlansky ME, Gokce N, Keaney JF Jr., Vita JA. The clinical implication of endothelial dysfunction. J Am Coll Cardiol 2003 42 : 1149 1160.
11. Stroes ES, Koomans HA, de Bruin TW, Rabelink TJ. Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication. Lancet 1995 346 : 467 471.
12. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997 95 : 1126 1131.
13. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004 109 (Suppl. III III39 III43.
14. Rosenson RS, Tangney CC. Anti-atherothrombotic properties of statins: Implications for cardiovascular event reduction. JAMA 1998 279 : 1643 1650.
15. American Diabetes Association. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997 20 : 1183 1197.
16. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilatation of the brachial artery: A report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002 39 : 257 265.
17. Matthews DR, Hosker JP, Rudenski AS, Neylor BA, Treacher DF, Turner RL. Homeostasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 28 : 412 419.
18. Philips DI, Clark PM, Hales CN, Osmond C. Understanding oral glucose tolerance: comparison of glucose and insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and secretion. Diabet Med 1994 11 : 286 292.
19. Woodman RJ, Chew GT, Watts GF. Mechanisms, significance and treatment of vascular dysfunction in type 2 diabetes mellitus. Focus on lipid-regulating therapy. Drug 2005 65 : 31 74.
20. Scuteri A, Tesauro M, Rizza S, Iantorno M, Federici M, Lauro D. Endothelial function and arterial stiffness in normotensive normoglycemic first-degree relatives of diabetic patients are independent of the metabolic syndrome. Nutr Metab Cardiovasc Dis 2008 18 : 349 356.
21. Ceriello A, Taboga C, Tonutti L, Quagliaro L, Piconi L, Bais B, Da Ros R, Motz E. Evidence for an independent and cumulative effect of postprandial hyper-triglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: Effects of short- and long-term simvastatin treatment. Circulation 2002 106 : 1211 1218.
22. Tsunekawa T, Hayashi T, Kano H, Sumi D, Matsui-Hirai H, Thakur NK, Egashira K, Iguchi A. Cerivastatin, a hydroxymethylglutaryl coenzyme A reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation 2001 104 : 376 379.
23. Sheu WH, Juang BL, Chen YT, Lee WJ. Endothelial dysfunction is not reversed by simvastatin treatment in type 2 patients with hypercholesterolemia. Diabetes Care 1999 22 : 1224 1225.
24. van Venrooij FV, van de Ree MA, Bots ML, Stolk RP, Huisman MV, Banga JD, for the DALI Study Group. Aggressive lipid lowering does not improve endothelial function in type 2 diabetes: The Diabetes Atorvastatin Lipid Intervention (DALI) study. A randomized, double-blind, placebo-controlled trial. Diabetes Care 2002 25 : 1211 1216.
25. Economides PA, Caselli A, Tiani E, Khaodhiar L, Horton ES, Veves A. The effects of atorvastatin on endothelial function in diabetic patients and subjects at risk for type 2 diabetes mellitus. J Clin Endocrinol Metab 2004 89 : 740 747.
26. Tamai O, Matsuoka H, Itabe H, Wada Y, Kohno K, Imaizumi T. Single LDL apheresis improves endothelium-dependent vasodilation in hypercholesterolemic humans. Circulation 1997 95 : 76 82.
27. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moyle LA, Goldman S, Flaker GC, Braunwald E, for the Cholesterol and Recurrent Events (CARE) Investigators. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholestrerol levels. Circulation 1998 98 : 839 844.
28. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Braunwald E, for the Cholesterol and Recurrent Events (CARE) Investigators. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 1999 100 : 230 235.
29. Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: The pravastatin inflammation/CRP evaluation (PRINCE): A randomized trial and cohort study. JAMA 2001 286 : 67 70.
30. Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflammation. Circ Res 2001 89 : 763 771.
31. Romano M, Mezzetti A, Marulli C, Ciabattoni G, Febo F, Di Ienno S, Roccaforte S, Vigneri S, Nubile G, Milani M, Davi G. Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholesterolemic patients: role of nitric oxide. J Investig Med 2000 48 : 183 189.
32. Robinson JG, Smith B, Maheshwari N, Schrott H. Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol 2005 46 : 1855 1862.